Compliance and tolerability evaluation of diacerein versus s-adenosyl methionine in osteoarthritis patients

Gayathri C.R.1*, Vanitha Samuel2, Senthilnathan A3, Nirmala P4

1Post Graduate, Department of Pharmacology, Rajah Muthiah Medical College, Annamalai University, Chidambaram, Tamil Nadu, India
2Professor, Department of Pharmacology, Rajah Muthiah Medical College, Annamalai University, Chidambaram, Tamil Nadu, India
3Professor, Department of Orthopaedics, Rajah Muthiah Medical College, Annamalai University, Chidambaram, Tamil Nadu, India
4Professor and HOD, Department of Pharmacology, Rajah Muthiah Medical College, Annamalai University, Chidambaram, Tamil Nadu, India
*Corresponding author email: gay3.gayu23@gmail.com

Abstract

Background: Diacerein and S-adenosyl methionine (SAMe) are symptomatic slow-acting drugs in osteoarthritis (SYSADOA). Diacerein is a semisynthetic, anthraquinone derivative, an interleukin 1beta inhibitor with anti-inflammatory, anti-catabolic and pro-anabolic properties on cartilage and synovial membrane. SAMe is a dietary supplement used in the management of OA. The objective of this study is to find out compliance and tolerability evaluation of Diacerein versus S-adenosyl methionine in patients suffering from Osteoarthritis.

Materials and methods: This was a prospective, randomized, interventional study conducted in Orthopedic OPD and ward in Rajah Muthiah Medical College and Hospital for a period of one year. A total of 80 patients were enrolled in this study as per the inclusion criteria. 40 patients in each group were randomly assigned to receive either diacerein 50mg BD or SAMe 200 mg TDS for 12 weeks. The NSAID diclofenac 50 mg BD was administered orally for a short course of one week to both the groups to relieve acute symptoms. Efficacy of both the drugs was assessed using Lysholm knee scoring scale. The tolerability profile was evaluated during each clinical visit on weeks 1, 4 and 12.
Results: Diacerein and SAMe which were symptomatic slow-acting drugs show a profound reduction in pain starting from 4th to 12th week of treatment. Lower GI side effects like diarrhoea were observed in the diacerein group and insomnia was reported in the SAMe group. Though the overall adverse effects were more in the diacerein group, compliance was better with regard to drug intake.

Conclusion: Both diacerein and SAMe were found to be effective in reducing the pain in Osteoarthritis patients. Diacerein with a good compliance factor was less tolerable because of the incidence of diarrhea. SAMe though better tolerated has a compliance score of fair to good.

Key words
Diacerein, S-adenosyl methionine, Diclofenac, Osteoarthritis.

Introduction
The common challenges that most countries face are the delivery of consistent, appropriate and high-quality health care standards within the limits of available resources. Over the last decade, several scientific societies involved in OA management produced guidelines for the management of hip, knee, and hand to improve quality and effectiveness of patient care. An epidemiological study of an urban Thai population suggested that the prevalence of symptomatic knee OA in Thailand is 34.5% among persons over 60 years of age [1]. 70% of all osteoarthritis is knee osteoarthritis and the risk for knee increases to 57% in those with a past H/O knee injury. The clinical manifestations include recurring episodes of pain, swelling, synovitis with effusion, stiffness & progressive limitation of motion.

Pharmacological therapies with analgesics and anti-inflammatory drugs form the mainstay of treatment for OA because of their well-established efficacy [2]. Long term use, especially in the elderly produces potentially serious adverse effects. Recently research in newer avenues has focused on the development of agents which improve the clinical symptoms of OA with better tolerability and safety profiles. Such symptomatic and slow acting drugs for OA (SYSADOA) [3] include Diacerein and S-adenosyl methionine (SAMe).

Diacerein one of the symptomatic slow-acting drugs for OA is a semi-synthetic anthraquinone derivative extracted from certain plants reduces the severity of OA and helps to modify the course of the disease [4]. It exerts its pharmacological action through its active metabolite-rhein [5]. Besides its anti-inflammatory properties, diacerein has been shown to have anti-catabolic [6] and pro-anabolic [7] effects on cartilage and synovial membrane, as well as protective effects against subchondral bone remodeling.

S-Adenosyl-L-methionine (SAMe), first discovered in 1952 [8], is formed from the essential amino acid methionine and adenosine triphosphate. SAMe is found in every living cell, where it functions as a donor of methyl groups in >100 different reactions catalyzed by methyltransferase enzymes. The potential benefit of SAMe in treating osteoarthritis was discovered when patients enrolled in clinical trials of SAMe for depression reported marked improvement in their osteoarthritis symptoms [9]. Experimental studies indicate that SAMe increases chondrocyte proteoglycan synthesis and proliferation rate [10].

In the current shift of understanding of the pathogenesis of osteoarthritis from biomechanical to biochemical, diacerein and SAMe holds a lot of promise in the management of osteoarthritis.

Materials and methods
Setting and Selection Criteria
The present study was a prospective, randomized interventional study of subjects with knee OA for a period of 12 weeks. This duration was chosen based on results observed in several studies,
which highlighted a delay of action by both drugs on the signs and symptoms of OA and to evaluate the drug safety, compliance and tolerability profile. This study was carried out in the Orthopaedic outpatient department of Rajah Muthiah Medical College and Hospital, Chidambaram from March 2016 to April 2017. Approval was obtained from Institutional Ethics Committee before initiating the study. A total of 80 patients were enrolled in the study after obtaining informed consent. Diagnosis as primary or secondary OA with unilateral or bilateral knee involvement was done by the Orthopedician. The clinical criteria for inclusion were adults 40 years or older, occurrence of symptomatic disease with pain present most days or crepitus on motion. The major criteria for exclusion were evidence of infection, polyarthralgia, rheumatoid arthritis, uncontrolled hypertension, Congestive heart failure, patients on drugs for psychiatric illness. Patients were not retained for the study if they had a serious concomitant medical illness or knee surgery planned within the following 6 months.

**Study Procedure**

Those who gave written consent to participate in the study were randomized into two groups. Forty patients in each group were assigned to receive either Diacerein (50 mg BD) or S-adenosyl methionine (200 mg TDS) daily for 12 weeks along with a short course of diclofenac 50 mg BD given to both groups for one week. All the drugs were administered orally after food intake. Study medications were dispensed once at baseline visit for one week and subsequently at the first follow up visit. Patients returned for assessment after the baseline visit at weeks 1, 4 and 12. Telephone calls at weeks 6 and 8 were made to ensure compliance during the follow-up period. No other systemic or intra-articular drugs for OA was allowed during the study. The data was recorded in a data sheet containing patient’s basic details. Clinical symptoms like pain, duration of the disease, morning stiffness and restricted movements with the final diagnosis was recorded.

**Drugs**

S-adenosyl methionine used in this study was enteric coated 200 mg tablets, marketed by Sun pharma laboratories Ltd. Diacerein capsules equivalent to diacerein IP 50mg manufactured by Glenmark Pharmaceuticals. Both the drugs was purchased from the local pharmacy. Tablet diclofenac 50mg from the hospital pharmacy was prescribed to the patients.

**Evaluation of efficacy**

The primary efficacy parameter was the patient’s assessment of pain on movement using Lysholm knee scoring scale with a total score of 100 grading of <65- poor, 65-83- fair, 84-90-good and >90-Excellent. An improvement in score indicates the reduction in pain level. Patients were assessed during each clinical visit at week 0 (baseline), 1st, 4th, and 12th week.

Treatment compliance was checked at each visit by counting the capsules. The compliance was considered as:

- excellent: no day of missed treatment,
- good: <3 days of missed treatment,
- fair: from 3 to 7 days of missed treatment,
- poor: >7 days of missed treatment.

**Evaluation of Safety**

All adverse effects reported by the patients during the study period were recorded on the Case report form and classified in terms of type, time of onset, severity, duration and outcome. Subjects were made aware of possible side effects during the first visit. Blood parameters including Rheumatoid factor and C-reactive protein were assessed to rule out Rheumatoid Arthritis. Adverse reactions were monitored with health diaries, clinical interviews at visits 1, 4 and 12 weeks. Subjects were asked to report adverse events if any by phone.

**Statistical Methods**

The statistical analysis was carried out with SYSTA 12 version software. Chi-square test (qualitative variable) has been applied. The
efficacy of both the drugs was assessed individually using one way ANOVA repeated measure test and blood parameters with 2×2 ANOVA repeated measures test. Level of significance was set at (P < 0.05).

Results

The pain score assessment by Lysholm knee scoring scale for individual drugs was as per Table – 1, 2.

Efficacy Results (vide Table – 1, 2)

The efficacy of the drugs was assessed mainly by the reduction in Osteoarthritic pain experienced by the patients. The degree of symptomatic joint pain was measured with the Lysholm knee scoring scale. An increase in the Lysholm knee score indicates the reduction in pain level. The mean pain score of both the drugs was evaluated. ‘One way ANOVA repeated measures test’ shows significant P-value with reduction in the pain levels in both the groups maximal at the end of 12th week.

The significant P-value of the comparison between baseline and 1st week, 1st to 4th week and 4th to 12th week ensures that both diacerein and SAMe are effective in reducing the pain level as assessed by “Repeated contrast test.”

Table - 1: Mean and SD of pain score of the subjects who have received diacerein-week wise.

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Mean</th>
<th>Std. Deviation</th>
<th>Onway ANOVA repeated measure F-value</th>
<th>p-value</th>
<th>Repeated contrast Test results</th>
<th>F value</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Week 0</td>
<td>44.2</td>
<td>8.2</td>
<td>161.8</td>
<td>&lt;0.001</td>
<td>Week 0 vs week 1</td>
<td>58.116</td>
<td>0.000</td>
</tr>
<tr>
<td>Week 1</td>
<td>49.75</td>
<td>7.7</td>
<td></td>
<td></td>
<td>Week 1 vs week 4</td>
<td>65.478</td>
<td>0.000</td>
</tr>
<tr>
<td>Week 4</td>
<td>57.8</td>
<td>7.6</td>
<td></td>
<td></td>
<td>Week 4 vs week 12</td>
<td>110.051</td>
<td>0.000</td>
</tr>
</tbody>
</table>

Values were expressed as Mean ± SD in each group. Values differ significantly at P ≤ 0.05. (One way ANOVA repeated measures test and repeated contrast test).

Table - 2: Mean and SD of pain score of the subjects who have received S-adenosylmethionine by week wise.

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Mean</th>
<th>Std. Deviation</th>
<th>Onway ANOVA repeated measure F-value</th>
<th>p-value</th>
<th>Repeated contrast Test results</th>
<th>F value</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Week 0</td>
<td>46.000</td>
<td>6.6178</td>
<td>201.790</td>
<td>&lt;0.001</td>
<td>Week 0 vs week 1</td>
<td>77.075</td>
<td>.000</td>
</tr>
<tr>
<td>Week 1</td>
<td>51.000</td>
<td>5.9226</td>
<td></td>
<td></td>
<td>Week 1 vs week 4</td>
<td>93.087</td>
<td>.000</td>
</tr>
<tr>
<td>Week 4</td>
<td>57.650</td>
<td>6.2205</td>
<td></td>
<td></td>
<td>Week 4 vs week 12</td>
<td>174.666</td>
<td>.000</td>
</tr>
<tr>
<td>Week 12</td>
<td>68.025</td>
<td>6.8706</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Values were expressed as Mean ± SD in each group. Values differ significantly at P ≤ 0.05. (One way ANOVA repeated measures test and repeated contrast test).

Safety Results

Mild to moderate diarrhea which was troublesome occurred in 12.5% in the diacerein group. Other GI side effects included abdominal pain 2.5% and dyspepsia of around 10% in the diacerein group. Only 7.5% and 2.5% in the SAMe group reported dyspepsia and gastritis respectively. Discolouration of urine was reported with Diacerein and mild to moderate hypersensitivity reactions were seen in few patients. Insomnia (7.5%) is one of the major adverse events which was observed in patients treated with SAMe. No
serious untoward event or adverse reactions occurred during the study. No clinically relevant differences were observed between any of the diacerein groups and the SAM group with regard to vital signs and clinical assessment parameters (Table – 3, 4).

**Table - 3:** Comparison of Adverse Effects in diacereinVs S-adenosylmethionine.

<table>
<thead>
<tr>
<th>Adverse effects</th>
<th>Group</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Diacerein</td>
<td>S-adenosyl methionine</td>
</tr>
<tr>
<td>Hypersensitivity reaction</td>
<td>1 2.5</td>
<td>1 2.5</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>1 2.5</td>
<td>0 .0</td>
</tr>
<tr>
<td>Bowel motility disorder</td>
<td>1 2.5</td>
<td>0 .0</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>5 12.5</td>
<td>0 .0</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>4 10.0</td>
<td>3 7.5</td>
</tr>
<tr>
<td>Gastritis</td>
<td>0 0</td>
<td>1 2.5</td>
</tr>
<tr>
<td>Nausea</td>
<td>2 5.0</td>
<td>3 7.5</td>
</tr>
<tr>
<td>Discolouration of urine</td>
<td>2 5.0</td>
<td>0 .0</td>
</tr>
<tr>
<td>Insomnia</td>
<td>0 0</td>
<td>3 7.5</td>
</tr>
</tbody>
</table>

**Table - 4:** Percentage of Adverse Effects in diacereinVs S-adenosyl methionine.

<table>
<thead>
<tr>
<th>Adverse effects</th>
<th>Diacerein</th>
<th>S-adenosyl methionine</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No.</td>
<td>%</td>
</tr>
<tr>
<td>Present</td>
<td>16</td>
<td>40.0</td>
</tr>
<tr>
<td>Absent</td>
<td>24</td>
<td>60.0</td>
</tr>
</tbody>
</table>

\( \chi^2 = 2.40 \) P. value 0.121 (NS)

**Table - 5:** Comparison of mean CRP levels between diacerein Versus S-adenosylmethionine in administered subjects.

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Group</th>
<th>2 x 2 ANOVA repeated measure</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Diacerein</td>
<td>S-adenosyl methionine</td>
</tr>
<tr>
<td>Mean</td>
<td>SD</td>
<td>Mean</td>
</tr>
<tr>
<td>Week 0</td>
<td>11.80</td>
<td>12.15</td>
</tr>
<tr>
<td>Week 12</td>
<td>5.17</td>
<td>2.43</td>
</tr>
</tbody>
</table>

Values were expressed as Mean ± SDin each group. Values differ significantly at P ≤ 0.05(2x2 ANOVA repeated measures test)

**Table - 6:** Comparison of mean RA factor levels between diacerein Versus S-adenosylmethionine in administered subjects.

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Group</th>
<th>2 x 2 ANOVA repeated measure</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Diacerein</td>
<td>S-adenosyl methionine</td>
</tr>
<tr>
<td>Mean</td>
<td>SD</td>
<td>Mean</td>
</tr>
<tr>
<td>Week 0</td>
<td>9.350</td>
<td>4.24</td>
</tr>
</tbody>
</table>

**Compliance**

Diacerein with a good compliance factor was less tolerable because of the incidence of diarrhea. SAME
The mean CRP levels at week 0 and week 12 when compared to the two groups of diacerein and SAMe showed statistical significance of P-value<0.05, whereas the mean CRP levels, when compared within groups, is not statistically significant (Table – 5).

The mean RA factors at week 0 and week 12 when compared to the two groups of diacerein and SAMe shows no statistical significance in their effects both between groups and following comparison within groups (Table – 6).

**Discussion**

This 12 week, prospective, randomized, Intervventional study including 80 patients of both sexes, aged 45-70 years suffering from knee osteoarthritis, was designed to evaluate the clinical efficacy, compliance, and tolerability of diacerein Vs S-adenosyl methionine. This study suggests that daily administration of diacerein 50 mg/day allows a significant improvement, which was also noted on the administration of three daily capsules of SAMe. In the light of these results, some SYSADOA has a positive risk-benefit balance for patients with OA. As a matter of fact, diacerein and SAMe have demonstrated pain reduction and physical improvement in function using the Lysholm knee scoring scale (Table – 1, 2).

Evidence published by Osteoarthritis Society International(OARSI) indicated that diacerein had a greater effect on pain reduction in OA than analgesics like paracetamol [11]. Although NSAIDs have shown a more rapid onset of action than diacerein, the efficacy of drugs such as Diclofenac on pain and joint function was comparable only after the first month of treatment.

In recent trends, there has been an increase in the use of symptomatic slow-acting drugs, connective tissue structure modifying agents like glucosamine or chondroitin sulfate and diacerein. Diacerein is an interleukin-1beta inhibitor. The cytokine interleukin-1beta plays a key role not only in cartilage degradation [12] but also in subchondral bone remodeling, chondrocyte apoptosis, and joint inflammation. Such drugs have a slow onset of efficacy and a longer carry-over effect once treatment is interrupted. S-adenosyl methionine is a dietary supplement used in the management of OA. It is known to reduce pain by increasing the synthesis of proteoglycans by human articular chondrocytes.

Regarding the adverse effects of diacerein, the most frequently reported were loose stools and diarrhea. Bartels, et al. [13] calculated that the risk ratio (RR) for developing diarrhea under diacerein versus placebo treatment was 3.51 (95% CI 2.55–4.83). Well in line with these meta-analyses, Rintelen, and co-authors [14] summarised that 39% of patients treated with diacerein versus 12% of patients receiving a placebo experienced at least one episode of loose stool or diarrhea.

Furthermore, lower GI symptoms decreased in most cases after prolonged treatment indicating tolerance to this effect. To minimise this risk, it is recommended to start diacerein treatment with half the prescribed dose (50 mg/day) for the first 2–4 weeks, the laxative properties of diacerein being dose-dependent [15]. Another major adverse effect reported with diacerein was discoloration of urine, due to the elimination of its metabolites, which is of no clinical significance. No incidence of upper GI effects such as gastric or duodenal ulcers was observed in the diacerein group indicating that diacerein does not inhibit COX and prostaglandins.

Nine clinical trials in Europe [16] and 1 in the United States [17] with a total of >22,000 participants have confirmed the therapeutic activity of SAMe against osteoarthritis. Oral administration of SAMe (400 mg for 7 days) to 4 subjects significantly increased SAMe concentrations in synovial fluid by 3–4-fold compared with pre-treatment values [18]. With effects similar to NSAID’s it is generally well tolerated, with adverse effects such as mild insomnia, loss of appetite,
constipation, nausea, dry mouth, sweating, dizziness, and restlessness [19]. Overall adverse effects were observed more in the diacerein group as compared to the SAMe group.

Dosing is one of the several factors affecting patient adherence to the treatment protocol. Reducing the frequency of dosing has been shown to improve patient compliance with medication regimens. In addition, several studies have shown that using single-dose regimens improves patient adherence [20]. Once- or twice-daily regimens are associated with better compliance than thrice-daily regimens [21]. We could then expect that the twice-daily dose of diacerein 50mg/day will improve patient’s compliance compared to a regimen of three daily capsules of 200mg of SAMe. However, a study designed for this purpose exclusively may help in confirming this fact. Our study showed a better compliance of patients in the diacerein group than in the SAMe group.

Elevated levels of CRP present in early OA predicts the progression of the disease [22]. The reduction in CRP values (Table - 4) with Diacerein was found to be more statistically significant than SAMe indicating a potent anti-inflammatory action (IL-1) [6]. RA factor (Table - 5), however was not significantly elevated both between groups and within group.

This study highlights the fact that though both the SYSADOA, diacerein and SAMe are effective in relieving pain after treatment for more than a month, their tolerability and compliance vary widely. SAMe though better tolerated has a compliance score of fair to good. Diacerein with a good compliance factor was less tolerable because of the incidence of diarrhea.

Conclusion
In conclusion, the benefit/risk ratio, indicate that the use of diacerein and S-adenosyl methionine could be of potential interest for the symptomatic management of OA. Both diacerein and SAMe were found to be effective in reducing the pain in Osteoarthritis patients. These drugs have a slow onset of action, with long term carryover effect and lesser side effects when compared to long term NSAIDS. But clinical trials focusing on their dose modification and duration of treatment would help rectify the issues relating to compliance and tolerability.

References